Every 10-Q that enVVeno Medical Corporation (NVNO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NVNO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVNO filings page.
enVVeno Medical Corporation develops the enVVe System, a first-in-class transcatheter replacement venous valve for patients with severe Chronic Venous Insufficiency. In April 2026, the FDA granted Investigational Device Exemption (IDE) approval for the TAVVE pivotal study, a two-stage trial of 230 patients at up to 40 U.S. sites that could support an FDA post-marketing submission one year after the 220th enrollment in stage two.
For the quarter ended June 30, 2026, enVVeno reported a net loss of $3.6 million, down from $6.7 million a year earlier, as operating expenses fell on lower VenoValve study costs and reduced stock-based compensation. Six-month net loss was $7.4 million versus $11.2 million. Cash and investments totaled $21.5 million with working capital of $20.2 million, and the company states these resources should fund operations into the third quarter of 2027, though it expects quarterly cash burn to rise to $4–$5 million in the second half of 2026 and acknowledges it will need additional capital over time.
enVVeno Medical Corporation reported a net loss of $3,849 thousand for the quarter ended March 31, 2026, narrowing from $4,503 thousand a year earlier as operating expenses fell. Research and development expenses declined to $2,111 thousand and selling, general and administrative costs decreased to $1,951 thousand, reflecting lower VenoValve study spending and reduced overhead.
The company held $24.9 million of cash and investments and $23.3 million of working capital as of March 31, 2026, and expects this to fund operations into the third quarter of 2027, even as quarterly cash burn is projected to rise to between $4 million and $5 million in 2026.
Strategically, enVVeno is pivoting from its surgical VenoValve, which received a non-approvable FDA letter in 2025, to the minimally invasive enVVe System. On April 29, 2026, the FDA approved its Investigational Device Exemption, allowing the pivotal TAVVE study of the transcatheter enVVe valve in severe deep Chronic Venous Insufficiency to begin, with up to 230 patients enrolled across as many as 40 U.S. sites.
enVVeno Medical (NVNO) filed its Q3 2025 10‑Q, reporting a net loss of $4.5 million as operating expenses declined. Research and development was $2.6 million and selling, general and administrative was $2.3 million for the quarter, reflecting lower legal costs and a partial recovery of previously reserved clinical prepayments.
Cash and investments totaled $31.0 million with working capital of $29.1 million as of September 30, 2025, and management believes resources are sufficient for at least one year. Shares outstanding were 20,216,176 as of October 28, 2025.
Regulatory updates: the FDA issued a not‑approvable letter for the VenoValve PMA on August 19, 2025; the company filed a supervisory appeal and met with FDA leadership in October, with a decision expected by year‑end 2025. Nasdaq notified the company on October 7, 2025 of non‑compliance with the $1.00 minimum bid price; NVNO has until April 6, 2026 to regain compliance.